You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Granules India inches up after USFDA nod for Ibuprofen tablets

Capital Market 

was up 0.29% to Rs 120.60 at 12:32 on after the company said that USFDA has approved abbreviated new drug applications for Ibuprofen Tablets USP, 200 mg filed by the company.

The announcement was made during market hours today, 13 October 2016.

Meanwhile, the S&P Sensex was down 319.08 points or 1.14% at 27,763.26.

On BSE, so far 1.33 lakh shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 122 and a low of Rs 120.10 so far during the day. The stock had hit a record high of Rs 164.45 on 1 December 2015. The stock had hit a 52-week low of Rs 101.25 on 12 February 2016. The stock had underperformed the market over the past one month till 10 October 2016, sliding 4.45% compared with 2.48% fall in the Sensex. The scrip had also underperformed the market in past one quarter, declining 15.58% as against Sensex's 3.52% rise.

The small-cap company has equity capital of Rs 21.72 crore. Face value per share is Rs 1.

said that the United States Food and Drug Administration (USFDA) has approved abbreviated new drug applications (ANDA) for Ibuprofen Tablets USP, 200 mg (OTC) filed by the company. The approved ANDAs is the bioequivalent to the reference listed drug product (RLD), Motrin IB Tablets, 200 mg, of Johnson & Johnson Consumer, Inc.

On a consolidated basis, Granules India's net profit rose 36.5% to Rs 38.96 crore on 6.6% growth in net sales to Rs 343.50 crore in Q1 June 2016 over Q1 June 2015.

produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients for customers in the regulated and semi-regulated markets.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Granules India inches up after USFDA nod for Ibuprofen tablets

Granules India was up 0.29% to Rs 120.60 at 12:32 IST on BSE after the company said that USFDA has approved abbreviated new drug applications for Ibuprofen Tablets USP, 200 mg filed by the company.

was up 0.29% to Rs 120.60 at 12:32 on after the company said that USFDA has approved abbreviated new drug applications for Ibuprofen Tablets USP, 200 mg filed by the company.

The announcement was made during market hours today, 13 October 2016.

Meanwhile, the S&P Sensex was down 319.08 points or 1.14% at 27,763.26.

On BSE, so far 1.33 lakh shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 122 and a low of Rs 120.10 so far during the day. The stock had hit a record high of Rs 164.45 on 1 December 2015. The stock had hit a 52-week low of Rs 101.25 on 12 February 2016. The stock had underperformed the market over the past one month till 10 October 2016, sliding 4.45% compared with 2.48% fall in the Sensex. The scrip had also underperformed the market in past one quarter, declining 15.58% as against Sensex's 3.52% rise.

The small-cap company has equity capital of Rs 21.72 crore. Face value per share is Rs 1.

said that the United States Food and Drug Administration (USFDA) has approved abbreviated new drug applications (ANDA) for Ibuprofen Tablets USP, 200 mg (OTC) filed by the company. The approved ANDAs is the bioequivalent to the reference listed drug product (RLD), Motrin IB Tablets, 200 mg, of Johnson & Johnson Consumer, Inc.

On a consolidated basis, Granules India's net profit rose 36.5% to Rs 38.96 crore on 6.6% growth in net sales to Rs 343.50 crore in Q1 June 2016 over Q1 June 2015.

produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients for customers in the regulated and semi-regulated markets.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Granules India inches up after USFDA nod for Ibuprofen tablets

was up 0.29% to Rs 120.60 at 12:32 on after the company said that USFDA has approved abbreviated new drug applications for Ibuprofen Tablets USP, 200 mg filed by the company.

The announcement was made during market hours today, 13 October 2016.

Meanwhile, the S&P Sensex was down 319.08 points or 1.14% at 27,763.26.

On BSE, so far 1.33 lakh shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 122 and a low of Rs 120.10 so far during the day. The stock had hit a record high of Rs 164.45 on 1 December 2015. The stock had hit a 52-week low of Rs 101.25 on 12 February 2016. The stock had underperformed the market over the past one month till 10 October 2016, sliding 4.45% compared with 2.48% fall in the Sensex. The scrip had also underperformed the market in past one quarter, declining 15.58% as against Sensex's 3.52% rise.

The small-cap company has equity capital of Rs 21.72 crore. Face value per share is Rs 1.

said that the United States Food and Drug Administration (USFDA) has approved abbreviated new drug applications (ANDA) for Ibuprofen Tablets USP, 200 mg (OTC) filed by the company. The approved ANDAs is the bioequivalent to the reference listed drug product (RLD), Motrin IB Tablets, 200 mg, of Johnson & Johnson Consumer, Inc.

On a consolidated basis, Granules India's net profit rose 36.5% to Rs 38.96 crore on 6.6% growth in net sales to Rs 343.50 crore in Q1 June 2016 over Q1 June 2015.

produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients for customers in the regulated and semi-regulated markets.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard